

Hospital Acquired Disease Testing Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Single User License: US \$ 4595

Multi User License: US \$ 7595

Corporate User License: US \$ 10595

[Buy Now](#)

[Request Sample](#)

Published Date: Jan 2014

87 Pages Report

REPORT DESCRIPTION

Hospital Acquired Disease Testing Market Expected to Reach USD 7.5 Billion Globally in 2019: Transparency Market Research

According to a new market report published by Transparency Market Research "Hospital Acquired Disease Testing Market (Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019", the global hospital acquired disease testing market was valued at USD 2.2 billion in 2012 and is expected to grow at a CAGR of 19.3% from 2013 to 2019, to reach an estimated value of USD 7.5 billion in 2019.

Nosocomial infections/hospital acquired diseases/hospital associated infections (HAI) form one of the critical areas of focus in the healthcare industry. Factors such as increasing prevalence of such conditions in neonatal and geriatric population, initiatives taken up by governments to manage nosocomial infections, increasing number of diseases that increases risk of hospital associated infections, and growing concerns about control and prevention of nosocomial infections worldwide will have a positive impact on the current hospital acquired disease testing industry.

The global hospital acquired disease testing market is segmented on the basis of type of infection and geography. Based on the different types of infection, this market is classified into pneumonia, urinary tract infection, blood stream infection, surgical site associated infection, MRSA infection testing and others. The hospital acquired urinary tract infection diagnostics segment occupies the largest market share in this category as prevalence and morbidity rate of this condition, and the demand for diagnostic solutions for the same is the

highest as compared to other hospital associated infections. It is expected that the global market for hospital associated urinary tract infection testing will reach USD 2,188.8 million in 2019 with the market growing at CAGR of 18.1% from 2013 to 2019. Furthermore, other testing solutions for conditions such as surgical site infections and pneumonia (hospital associated and ventilator associated infections) will also experience high demand in lesser developed regions of Asia-Pacific, Latin America and other developing countries where the prevalence of such conditions is higher. It is expected that the market for surgical site infections will grow at a CAGR of 20.1% during the given period of forecast.

Geographically, United States and Canada together are the leaders in the global hospital acquired disease testing market with a combined market share (of the North American region) of 41.3% in 2012. Some of the major growth drivers for the North American nosocomial infection testing market include existence of highly developed healthcare infrastructure, high rate of implementation of healthcare guidelines given by regulatory and guiding institutions such as Centers for Disease Control and Prevention (U.S.), and increasing awareness about these diseases and their prevention. The European Union considers infectious diseases as an increasing threat to the general public health; the public health system in this region is increasingly engaging itself in conducting dialogue between healthcare providers and medical practitioners for developing better, faster and cost effective methods for nosocomial infection management and prevention. Asian countries including China, Philippines and India are the most potential markets for such diagnostic and testing solutions owing to existence of factors such as higher population, poor hospital infrastructure, lack of adherence to sanitation procedures and therefore higher disease prevalence growth rates. UAE and African countries are some of the lucrative markets in the Rest of the World (RoW).

Molecular diagnostics solutions play a vital role in this market as they offer precise, faster and cost effective diagnosis for various nosocomial infections. Considering the market competition, the global hospital acquired infection testing market is highly fragmented and is characterized by the existence of several large and mid-sized diagnostic solution providers. Some of the key market players contributing to this industry include Diatherix Laboratories Inc., Gen-Probe Inc., Qiagen GmbH, L Hoffman La Roche, Cepheid, Inc., Life Technologies Corporation, Meridian Biosciences, Cantel Medical Corporation, Nordion, Inc. and others.

The global hospital acquired disease testing market is segmented as follows:

Hospital Acquired Disease Testing Market, by Infection Type

- Pneumonia infection
- Urinary tract infection
- Blood stream associated infection
- Surgical site infection
- MRSA infection

Hospital Acquired Disease Testing Market, by Geography

- North America
- Europe
- Asia-Pacific
- Rest of the World

TABLE OF CONTENTS

Chapter 1 Introduction

- 1.1 Report Description
- 1.2 Market Segmentation
- 1.3 Research Methodology
- 1.4 List of Abbreviations

Chapter 2 Executive Summary

Chapter 3 Market Overview

3.1 Overview – Current Market Scenario and Future Market Trends

3.1.1 Global Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)

3.2 Drivers

3.2.1 Establishment of Government Guidelines and Code of Prevention of HAIs

3.2.2 Increasing Prevalence of HAIs and Rise in the Number of Drug Resistant Pathogens

3.2.3 Expiration of Patents of Basic PCRs

3.3 Restraints

3.3.1 Lack of Budget and Skilled Labour in Developing Countries

3.3.2 Stringent Regulations and Guidance Framework

Browse the full report with TOC: <http://www.transparencymarketresearch.com/hospital-acquired-disease-testing.html>

3.3.3 Lack of Controlling Authorities and Control Programmes in Less Developed Regions

3.4 Opportunities

3.4.1 Passing of the Patient Care and Affordable Care Act in the United States

3.4.2 Technological Developments in the Field of Molecular Diagnostics

3.5 Porter's Five Force Analysis for the Global Hospital Acquired Disease Testing Market

3.5.1 Bargaining Power of Suppliers

3.5.2 Bargaining Power of Buyers

3.5.3 Threat of New Entrants

3.5.4 Threat of Substitutes

3.5.5 Competitive Rivalry

3.6 Market Attractiveness Analysis of Global Hospital Acquired Disease Testing Market, by Geography

Chapter 4 Global Hospital Acquired Disease Testing, by Infection Type

4.1 Overview – Current Market Scenario and Future Market Trends

4.1.1 Global Hospital Acquired Disease Testing Market, 2011 – 2019 (USD Million)

4.2 Urinary Tract Infection (UTI) Testing

4.2.1 Global Urinary Tract Infection Testing Market Revenue, 2011 – 2019 (USD Million)

4.3 Surgical Site Infection (SSI) Testing

4.3.1 Global Surgical Site Infection (SSI) Testing Market Revenue, 2011 - 2019 (USD Million)

4.4 Pneumonia Testing

4.4.1 Global Pneumonia Testing Market Revenue, 2011 - 2019 (USD Million)

4.5 Blood Stream Infection (BSI) Testing

4.5.1 Global Blood Stream Infection Testing Market Revenue, 2011 - 2019 (USD Million)

4.6 Methicillin-resistant Staphylococcus Aureus (MRSA) Testing

4.6.1 Global Methicillin-resistant Staphylococcus Aureus (MRSA) Testing Market Revenue, 2011 - 2019 (USD Million)

4.7 Others (GI, Bone, Respiratory, Cardiovascular, Etc.)

4.7.1 Global Other (GI, Joints, Respiratory, Cardiovascular, Etc.) Infections Testing Market Revenue, 2011 - 2019 (USD Million)

4.7.2 Respiratory Infections

4.7.3 Bone Infections

4.7.4 Cardiovascular Infections

4.7.5 Gastrointestinal Infections

Related & Recently Published Reports by Transparency Market Research

Unsaturated Polyester Resin Market:

<http://www.transparencymarketresearch.com/unsaturated-polyester-resin.html>

Caprolactam Market: <http://www.transparencymarketresearch.com/caprolactam-markat.html>

Latin America Adhesives and Sealants Market:

<http://www.transparencymarketresearch.com/latin-america-adhesives-sealants-industry.html>

Chapter 5 Global Hospital Acquired Disease Testing, by Geography

5.1 Overview – Current Market Scenario and Future Market Trends

5.1.1 Global Hospital Acquired Disease Testing Market Revenue, by Geography, 2011-2019 (USD Million)

5.2 North America

5.2.1 North America Hospital Acquired Disease Testing Market Revenue, 2011 - 2019 (USD Million)

5.2.2 North America Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)

5.3 Europe

5.3.1 Europe Hospital Acquired Disease Testing Market Revenue, 2011 – 2019 (USD Million)

5.3.2 Europe Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)

5.4 Asia-Pacific

5.4.1 Asia-Pacific Hospital Acquired Disease Testing Market Revenue, 2011 – 2019 (USD Million)

5.4.2 Asia-Pacific Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)

5.5 Rest of the World (RoW)

5.5.1 Rest of the World (RoW) Hospital Acquired Disease Testing Market Revenue, 2011 – 2019 (USD Million)

5.5.2 RoW Hospital Acquired Disease Testing Market Revenue, by Infection Type, 2011 – 2019 (USD Million)

Chapter 6 Recommendations

6.1 Educating and Training Hospital Staff

6.2 Focus on Expansion in Emerging Economies

6.3 Regulatory Compliance

6.4 Adapt to the Needs of Different Consumer Types

Chapter 7 Company Profiles

7.1 Abbott Laboratories, Inc.

7.1.1 Company Overview

7.1.2 Financial Overview

7.1.3 Business Strategies

7.1.4 Recent Developments

7.2 Alere, Inc.

7.2.1 Company Overview

7.2.2 Financial Overview

7.2.3 Business Strategies

7.2.4 Recent Developments

7.3 Becton, Dickinson and Company

7.3.1 Company Overview

7.3.2 Financial Overview

7.3.3 Business Strategies

7.3.4 Recent Developments

7.4 bioMerieux, Inc.

7.4.1 Company Overview

7.4.2 Financial Overview

7.4.3 Business Strategies

7.4.4 Recent Developments

7.5 Cantel Medical Corporation

7.5.1 Company Overview

7.5.2 Financial Overview

7.5.3 Business Strategies

7.5.4 Recent Developments

7.6 Cepheid, Inc.

7.6.1 Company Overview

7.6.2 Financial Overview

7.6.3 Business Strategies

7.7 Diatherix Laboratories Inc.

7.7.1 Company Overview

7.7.2 Business Strategies

7.7.3 Recent Developments

7.8 Gen-Probe, Inc.

7.8.1 Company Overview

7.8.2 Financial Overview

7.8.3 Business Strategies

7.8.4 Recent Developments

7.9 F. Hoffman-La Roche, Ltd.

7.9.1 Company Overview

7.9.2 Financial Overview

7.9.3 Business Strategies

7.9.4 Recent Developments

7.10 Life Technologies Corporation

7.10.1 Company Overview

7.10.2 Financial Overview

7.10.3 Business Strategies

7.10.4 Recent Developments

7.11 Meridian Bioscience, Inc.

7.11.1 Company Overview

7.11.2 Financial Overview

7.11.3 Business Strategies

7.11.4 Recent Developments

7.12 Nordion, Inc.

7.12.1 Company Overview

7.12.2 Financial Overview

7.12.3 Business Strategies

7.12.4 Recent Developments

7.13 Qiagen GmbH

7.13.1 Company Overview

7.13.2 Financial Overview

7.13.3 Business Strategies

7.13.4 Recent Developments

About Us:

Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: <http://www.transparencymarketresearch.com/>

Browse the full report with TOC: <http://www.transparencymarketresearch.com/hospital-acquired-disease-testing.html>